Prudence Pharma Chem to set up bulk drug unit at Ankleshwar in Bharuch district of Gujarat with an investment of Rs. 11.7 million. . It is proposed to stop the existing products and to manufacture various other bulk drugs and intermediates with installed capacity of 10 MTPM within the same premises. Besides 12 MTPM of Bulk Intermediates and by-products will be manufactured.
Details of products along with their production capacity are given below:
Sr. No. | Name of Products | Chemical Name of Product | Capacity, MT/Month |
Group A | |||
A-1. | Losarton Potassium (LSR) | (2-n-butyl-4-chloro-5-hydroxy-methyl-1-[(2`-(1H-tetrazol-5-yl potassium OR OR [1- {2`- (2H-tetrazol-5-yl) biphenyl -4-yl}methyl]-2-butyl-4-chloro-1H-imidazol -5-yl) methanol potassium | 3.0 |
A-2. | Metaxalone (MX) | 5-[(3,5-dimethylphenoxy)methyl]oxazolidin-2-one OR 5-(3,5-Dimethyl Phenoxy methyl)-2-oxazolidinone | |
A-3. | Amlodipine Besylate (AMB) | 3-Ethyl 5-methyl (4RS)-2-[(2-aminoethoxy) methyl]-4-(2-chlorophenyl)-6-methyl-1, 4-dihydropyridine-3, 5-dicarboxylate benzenesulphonate. | |
Group B | |||
B-1. | Glibenclamide (GLB) | 1-[{4-(2-[(5-Chloro-2-ethoxybenzoyl) amino] ethyl) phenyl} sulphonyl]-3-cyclohexylurea. | 7.0 |
B-2. | Niclosamide | 5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide | |
Total Capacity (Group A + B) | 10.0 |
List of Intermediate Products
Sr. No. | Production Stage | Chemical Name of Intermediate product | Kg/Kg of Finished product | Capacity, MT/Month |
Group A | ||||
A-1 | Stage 1 (LSR -1) | 3-Butyl-4-chloro 5-methyl hydroxy N-(4-methyl 2-cyno biphenyl) imidazole | 1.25 | 3.75 |
Stage 2 (LSR -2) | 1.00 | 3.00 | ||
A-2 | Stage -1 (MX- 1) | 2-[(3,5-dimethylphenoxy)methyl]oxirane | 2.32 | 6.96 |
Stage -2 (MX- 2) | 1-amino-2-(3,5-dimethylphenoxy)ethanol | 1.67 | 5.01 | |
A-3 | Stage -1 (AMB- 1) | Hydroxy ethyl Phthlamide [HEP ] | 1.35 | 4.05 |
Stage -2 (AMB- 2) | Methy 3 Amino Crotonate [MAC] | 2.00 | 6.00 | |
Stage -3 (AMB- 3) | Ethyl -4-(2-Phthlamide) ethyl aceto acetate. [PHEMA] & Phthloyal Amlodipine | 1.50 | 4.50 | |
Stage -4 (AMB- 4) | 1.00 | 3.00 | ||
B-4 | Stage -2 (GLB 2) | Sulphonamide | 0.72 | 5.04 |
| Maximum Capacity | Group A |
| 6.96 |
Group B |
| 5.04 | ||
|
| Total Capacity (Group A + B) |
| 12.00 |
* The unit may sale intermediate products at any stage as stated above from the manufacturing of each product.
* The maximum production capacity of intermediate products will not exceed 12.00 MT/Month
List of By-Products
Sr. No. | Source | Name Of The Byproducts | Capacity, MT/Month |
GROUP A | |||
1. | APCE for Metaxalone (A -2 ) | 150.00 | |
GROUP - B | |||
1. | APCE for Glibenclamide (A -2 ) | 6.70 | |
9.80 | |||
2. | APCE for Niclosamide (A -2 ) | 3.00 | |
4.40
| |||
|
|
|
|
150.00 | |||
6.70 | |||
9.80 |
|
Alembic to expand its drug unit at Vadodara in Gujarat with an investment of Rs. 2690 million. The project involves expanding Penicillin G- manufacturing unit from 83.33 MMU to 240 MMU
Details of products and with their production capacities are given below:
SR. NO. | NAME OF PRODUCT | CAPACITY (PER MONTH) | |
EXISTING | TOTAL AFTER PROPOSED EXPANSION | ||
| Penicillin G | 83.33 MMU | 240 MMU |
| Erythromycin (Thio) | 10.5 T | 10.5 T |
| Erythromycin Estolate | 7.4 T | 7.4 T |
| Protinules Powder | 20 T | - |
| Tablets and capsules | 150 lacs Tablet & 5 lacs Capsules | - |
| Injectables (dry powder) | 10 T | - |
| Liquid oral preparations | 16 lacs unit | - |
| Roxithromycin | 5 T | 5 T |
| Cephalosporin - C | 10 T | 10 T |
| Sod. Penicillin G | 12 MMU | 12 MMU |
| Benzathine Penicillin G | 2.5 T | 2.5 T |
| Procaine Penicillin G | 14.5 MMU | 14.5 MMU |
| Sterile Azithromycin | 200 kg | - |
| Dried Yeast Powder | 9.85 T | 9.85 T |
| Rofecoxib | 360 Kg | 360 Kg |
| Pioglitazon HCL | 15 Kg | 15 Kg |
| Mosapride Citrate | 15 Kg | 15 Kg |
| Meloxicam | 48 Kg | 48 Kg |
Note : 1 MMU Penicillin = 1000 BU = Approx. 640 Kg. |
Production of product no. 4 to 7 & 13 already stopped since 2003
. Details of products and their production capacities are given below:
Sr. No. | Product | Capacity (MTPM) |
Existing | ||
1 | 2:4:5 Tri Chloro Nitro Benzene | 2 |
2 | Spent Sulphuric Acid | 3 |
Proposed | ||
1 | Gabapentine HCl | 30 |
2 | Glimipiride HCl | 25 |
3 | Lamotrigine | 30 |
4 | Lidocaine HCl | 15 |
5 | Phenyl Propyl Amine HCl | 25 |
6 | Quinine Sulphate | 3 |
7 | Terbutaline Sulphate | 20 |
8 | Venlafexine HCl | 15 |
9 | Para Anisyl Alcohol | 50 |
10 | Salbutamol Sulphate | 5 |
11 | Meta Phenoxy Benzyl Alcohol | 30 |
12 | Phenanthrene | 20 |
13 | Oxcarbazepine | 20 |
14 | Meta Bromo Anisol | 20 |
15 | Sucralfate | 30 |
* The unit proposes to manufacture 50 MT/month any of the above product individually or combination from any above product.
JNP Products to expand its bulk drug unit at Jhagadia in Bharuch district of Gujarat with an investment of Rs. 150 million. Presently the unit is manufacturing 4 Amino Phenol (PAP Slurry) at a production capacity of 500 MTPM which is used for manufacturing paracetamol. After expansion, production capacity will increase to 1650 MTPM. The land available with the company is 26000 m2. Expansion will be carried within the existing unit.
11,950 ₹ | 4950 ₹ | 4950 ₹ | 4950 ₹ | 3950 ₹ |
Copyright © 2013 Ibis Research Information Services Pvt Ltd. All Rights Reserved.
Contact : Ibis Research Information Services Pvt Ltd., 28, Rajaji Street, NGO Colony
Guduvancherry, Chennai -603 202 Mobile : 0-97898-37940 email : [email protected] Privacy Policy